ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
72.53
+0.69 (+0.96%)
At close: 4:01PM EST

72.52 -0.01 (-0.01%)
After hours: 6:44PM EST

Stock chart is not supported by your current browser
Previous Close71.84
Open72.81
Bid0.00 x 2200
Ask0.00 x 800
Day's Range72.49 - 73.86
52 Week Range54.63 - 74.92
Volume6,883,761
Avg. Volume6,904,509
Market Cap127.387B
Beta (3Y Monthly)1.51
PE Ratio (TTM)145.94
EPS (TTM)0.50
Earnings DateJan 22, 2019 - Jan 28, 2019
Forward Dividend & Yield1.12 (1.60%)
Ex-Dividend Date2018-10-12
1y Target Est79.44
Trade prices are not sourced from all markets
  • Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
    Zacks2 hours ago

    Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

    Abbott (ABT) closed the most recent trading day at $72.53, moving +0.96% from the previous trading session.

  • InvestorPlace9 hours ago

    5 Pharma Stocks That Could Cure Ailing Portfolios in 2019

    The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations.

  • A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019
    Market Realist5 hours ago

    A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019

    Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018. Medtronic’s net income in the first half of fiscal 2019 totaled $2.2 billion compared to $3.0 billion in the same period the prior year. Wall Street analysts anticipate that Medtronic is expected to report net income of $1.25 billion in the third quarter of fiscal 2019.

  • How Medtronic’s Revenues and Expenses Are Trending
    Market Realist7 hours ago

    How Medtronic’s Revenues and Expenses Are Trending

    Medtronic (MDT) reported net revenues of $7.5 billion in the second quarter of fiscal 2019 compared to $7.1 billion in the second quarter of fiscal 2018, reflecting 6% YoY growth.

  • How Wall Street Analysts View Medtronic in December
    Market Realist8 hours ago

    How Wall Street Analysts View Medtronic in December

    In November, Medtronic announced that the company would acquire Nutrino Health, a company that specializes in nutrition associated data services, analytics, and technologies. Medtronic’s diabetes segment is expected to improve significantly with the acquisition of Nutrino Health. The acquisition of Nutrino Health will bring together Nutrino Health’s robust food database, expertise in nutrition science and food analysis systems, and Medtronic’s innovative diabetes management resources.

  • TheStreet.comyesterday

    Shire, Abbott Labs May Pace Healthcare Stocks in 2019

    Shire is a pharmaceutical company, with a wide range of products approved for use around the world. Some of the more familiar drugs the company produces include Adderall, prescribed for adult ADD, and Pentasa, used to treat Crohn's and other inflammatory bowel diseases. The company possesses both strength and weakness, and both are evident in the most recent quarterly report.

  • Will GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?
    Market Realistyesterday

    Will GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?

    Why Has General Electric Stock Struggled in 2018? The Healthcare segment is the fourth-largest contributor to General Electric’s total revenues. As part of the company’s major restructuring plan in June, General Electric intends to spin off the segment and turn it into a standalone entity.

  • How Much Upside Do Analysts Expect in Endo Stock?
    Market Realistyesterday

    How Much Upside Do Analysts Expect in Endo Stock?

    In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating. The mean rating for Endo International stock is 2.5 with a target price of $17.04, implying an upside potential of 47.3% over Endo International’s closing price of $11.57 on December 7, 2018.

  • PR Newswireyesterday

    Abbott to Present at J.P. Morgan Healthcare Conference

    ABBOTT PARK, Ill., Dec. 11, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019 . Brian Yoor , executive vice president of ...

  • What Endo International’s Bottom Line Trend Indicates
    Market Realist2 days ago

    What Endo International’s Bottom Line Trend Indicates

    How's Endo International Positioned in December? Endo International (ENDP) incurred net interest expenses of $131.85 million in the third quarter of 2018 as compared with $127.52 million in the year-ago period. Endo International’s net loss per share was $0.43 in the third quarter of 2017.

  • Generic-drug stocks slammed by report of expanded price-fixing probe
    MarketWatch2 days ago

    Generic-drug stocks slammed by report of expanded price-fixing probe

    Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry.

  • How Endo International’s Gross Margin Has Trended
    Market Realist2 days ago

    How Endo International’s Gross Margin Has Trended

    Endo International’s (ENDP) next two business segments are: The US Generic Pharmaceuticals segment includes solid oral extended release, solid oral immediate release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. Revenues from this segment declined from $294.75 million in the third quarter of 2017 to $257.97 million in the third quarter of 2018. The International Pharmaceuticals segment revenues also declined from $56.43 million in the third quarter of 2017 to $30.25 million in the third quarter of 2018.

  • MarketWatch2 days ago

    Generic drug makers stocks fall sharply after report of expanded price-fixing probe

    Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing. The case now involves at least 16 companies and 300 drugs, the report said, citing Joseph Nielsen, an assistant attorney general and antitrust investigator in Connecticut, who has been a leader in the probe. Nielsen is quoted as saying, "this is most likely the largest cartel in the history of the United States." The victims were consumers and taxpayers, who have been carrying the high cost of overcharges on common antiboitics, blood-pressure medications, arthritis treatments, anxiety pills and more, said the report. Teva Pharmaceuticals Industries Ltd. ADRs fell 5.7% on the news. Mylan NV was down 4.6%, and Dr. Reddy Labs Ltd was down 3%. Abbott Labs was down 1.4% and Pfizer Inc. was down 1.6%. The S&P 500 was down 1.8% and the Dow Jones Industrial Average was down about 2%.

  • Is Abbott Laboratories (ABT) A Good Stock To Buy?
    Insider Monkey4 days ago

    Is Abbott Laboratories (ABT) A Good Stock To Buy?

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish […]

  • CNBC5 days ago

    Cramer's lightning round: There are better drug stocks to own than GlaxoSmithKline

    Jim Cramer flies through his responses to callers' stock questions, including one about the prospects for a drugmaker's stock.

  • Investing.com5 days ago

    Abbott Labs Falls 3%

    Investing.com - Abbott Labs (NYSE:ABT) fell by 3.02% to trade at $69.38 by 14:11 (19:11 GMT) on Friday on the NYSE exchange.

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: Boston Scientific and Abbott Laboratories

    Boston Scientific’s stock moved 5.17% lower Tuesday, to close the day at $36.52. The stock recorded a trading volume of 8,966,181 shares, which was above its three months average volume of 7,581,259 shares. In the last year, Boston Scientific’s shares have traded in a range of 24.54 - 39.44.

  • Investing.com8 days ago

    Abbott Labs Falls 3%

    Investing.com - Abbott Labs (NYSE:ABT) fell by 3.04% to trade at $72.01 by 13:27 (18:27 GMT) on Tuesday on the NYSE exchange.

  • InvestorPlace9 days ago

    AbbVie Stock Could Become a New Happy Pill for Investors

    While AbbVie (NYSE:ABBV) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. Although the concerns may be overblown, losing any patent protection on the widely prescribed drug breeds the type of uncertainty that often leads to stock declines. What gives investors confidence in the shares, though, is a promising drug pipeline should keep AbbVie stock on a growth trajectory even as Humira fades as a significant revenue contributor.

  • 3 Beaten-Down Biotech Stocks to Buy Before the End of 2018
    InvestorPlace12 days ago

    3 Beaten-Down Biotech Stocks to Buy Before the End of 2018

    Biotech stocks, like the rest of the broader market, have been under heavy pressure in late 2018. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which includes several of the largest biotechnology stocks, and the SPDR S&P Biotech ETF (NYSEARCA:XBI), which also includes the sectors sector’s mid- and small-cap companies, have been in a free-fall since October, declining over 15% each. Although many of these biotech stocks, including AbbVie (NYSE:ABBV), Celgene (NASDAQ:CELG) and Mylan (NASDAQ:MYL), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet.